• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    N

    Nagoya Medical Center

    EST. 1982
    1,502论文总数
    3.8万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1502)

    年份
    起
    –
    止
    排序
    1Pathological Evolution of Fibrosis in IgG4-Related Ophthalmic Disease: A Retrospective Study of 100 Cases
    Natsuki Taniguchi,Akira Satou,Yasuharu Sato,Taishi Takahara,Yasuhiro Takahashi,Toshinobu Kubota,Akari Iwakoshi,Toyonori Tsuzuki

    IgG4-related ophthalmic disease (IgG4-ROD) is a common manifestation of IgG4-related disease, but its clinicopathologic features and the mechanisms underlying fibrosis remain incompletely understood. We retrospectively analyzed 100 cases of IgG4-ROD and investigated fibrosis using immunohistochemistry for IgG4, FOXP3, CD68, and CD163, together with RNA in situ hybridization for TGFB1. IgG4-ROD was histologically categorized into four patterns (Patterns 1-4) reflecting progressive fibrosis, demonstrating a spectrum from lymphoplasmacytic inflammation to marked fibrosis. Fibrosis was absent or minimal in 51% of cases, indicating that fibrosis is not essential for diagnosis, whereas obliterative phlebitis was rare. Compared with non-fibrotic cases, fibrotic cases showed significantly increased numbers of CD68-positive and CD163-positive macrophages (p < 0.001), predominantly localized at the interface between lymphoid and fibrotic areas. In contrast, fibrosis was not associated with IgG4-positive plasma cells, FOXP3-positive regulatory T cells, or EBV status. TGFB1 expression was significantly higher in lymphocyte-rich than fibrotic areas (p < 0.001), suggesting a closer association with lymphocyte-rich inflammation than established fibrosis. These findings demonstrate progressive histologic changes from Pattern 1 to Pattern 4 and suggest that accumulation of CD163-positive macrophages is associated with fibrosis in IgG4-ROD.

    2026PATHOLOGY INTERNATIONAL(2026)
    引用
    AI阅读
    加入学术空间
    2Impact of BMI on LVAD Explantation - A VAD WEAN Network Analysis
    S. Sundaravel, O. Gilbert, B. Pisani, H. Hattori, I. Karabayir, S. Rojas Hernandez, M. Ruiz Cano, J. Schmitto, S. Patel, S. Drakos, Y. Barac
    2026JOURNAL OF HEART AND LUNG TRANSPLANTATION(2026)
    引用
    AI阅读
    加入学术空间
    3Artificial Intelligence Modelling in Grading Breast Phyllodes Tumours.
    Jessica Ee Ting Koong,Abubakr Shafique,Nur Diyana Md Nasir, Aaron Han, Oi Harada,Soon Lee,Rieko Nishimura,Yasuyo Ohi, Hamid R Tizhoosh,Puay Hoon Tan

    BACKGROUND:Breast phyllodes tumours (PT) are rare biphasic neoplasms consisting of epithelial and stromal components. They are classified into benign, borderline and malignant categories. Diagnosing and grading PTs present a challenge for pathologists, as there are multiple histological parameters and their own tiers. We aim to investigate the potential role of artificial intelligence (AI) as a diagnostic aid in determining PT grade. MATERIALS AND METHODS:We investigated 15 PT whole slide images (WSIs), comprising 5 benign, 5 borderline and 5 malignant cases. We sought to classify and retrieve the most relevant WSIs by matching histological features at different patch sizes, using the Yottixel framework for WSI processing. Patches were extracted at a 20× magnification level. We then used the KimiaNet to extract feature vectors and transformed these into barcode representations. Barcodes of a query WSI were compared with those of others in the archive, allowing us to identify the most similar WSI and determine the PT grades from histological similarities. RESULTS:We utilized 'majority-n accuracy' as a measure of correctness, that is when the majority of the top-n search results have the correct diagnosis as the query patient. We achieved a maximum reported accuracy of 67%, with a 3000 × 3000 patch size when grading PT at majority voting with n = 4. CONCLUSION:Despite the small sample size and absence of fine-tuning, our study demonstrated the potential of AI-based PT grade stratification using various patch sizes through histological matching. This serves as a preliminary proof of concept, with the prospect of refinement for potential routine clinical application.

    2026Histopathology(2026)
    引用
    AI阅读
    加入学术空间
    4Telisotuzumab Adizutecan (ABBV-400), a Novel C-Met-targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
    John H Strickler,Judith Raimbourg, Jonathan E Cohen,François Ghiringhelli, Manish R Sharma, Chiyoe Kitagawa,Ki Hyeong Lee,Bert O'Neil, María de Miguel, Esma Saada-Bouzid, Rui Li, Nandini Rudra-Ganguly,

    Abstract Purpose: Gastrointestinal tumors, including esophageal and gastric/gastroesophageal junction adenocarcinoma (GEA), have a high mortality rate and present significant treatment challenges. Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel antibody–drug conjugate targeting the c-Met protein (also known as MET protein), has shown encouraging results in patients with advanced GEA. Patients and Methods: This phase I, open-label, multicenter study assessed the safety, efficacy, and pharmacokinetics (PK) of Temab-A monotherapy (3 mg/kg every 3 weeks intravenously) in patients with advanced GEA. Patients ≥18 years of age with advanced/metastatic GEA who had received 1 to 2 prior systemic therapies were included. The primary objectives were the evaluation of safety, PK, and efficacy; efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). c-Met expression and MET amplification were retrospectively assessed. Results: Forty-two patients with advanced GEA were enrolled; the median age was 60 years. The median follow-up duration was 12.6 months. All patients had one or more treatment-emergent adverse events (TEAE), with 88% experiencing grade ≥3 TEAEs. The most common hematologic TEAEs were anemia (67%), nausea (52%), and decreased appetite (36%). The ORR was 29%, the clinical benefit rate was 71%, and the median DOR was 4.2 months. The median PFS was 4 months, and the median OS was 5.8 months. Exploratory biomarker analyses showed ORR enrichment in patients with higher c-Met protein expression and MET focal amplification. Conclusions: Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.

    2026Clinical cancer research an official journal of the American Association for Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    5The Yokohama System for Breast Cytology in Japan: A Multicenter Comparison of the International Academy of Cytology Yokohama System and the Conventional Japanese System for Reporting Breast Fine-Needle Aspiration Biopsy.
    Akiyoshi Hoshino,Ichiro Maeda,Rieko Nishimura, Eiji Abe,Yuji Kozuka,Shinobu Masuda,Yasuyo Ohi,Takashi Sakatani,Hitoshi Tsuda, Hitoshi Ito,Shin-Ichi Tsuchiya,Robert Osamura,

    BACKGROUND The International Academy of Cytology (IAC) recently introduced the Yokohama System (IAC-YS) for reporting breast fine-needle aspiration biopsy (FNAB) cytology. The Working Group on the Accuracy of Breast Fine-Needle Aspiration Cytology of the Japanese Society of Clinical Cytology aimed to categorize breast FNAB specimens according to the IAC-YS, assess the risk of malignancy (ROM) for each category, and evaluate the diagnostic yield of breast FNAB in Japan. METHODS Breast FNAB specimens obtained between January 2010 and December 2019 from nine cooperating facilities were retrospectively reclassified following the IAC-YS. The ROM for each category was calculated and compared with that using the conventional Japanese diagnostic system (CJS). Diagnostic yield was evaluated using a five-category approach to distinguish benign from malignant samples. RESULTS In total, 1727 samples from 1722 patients were distributed as follows: Category 1 (insufficient material), 21.3%; Category 2 (benign), 38.9%; Category 3 (atypical), 6.9%; Category 4 (suspicious for malignancy), 10.0%; and Category 5 (malignant), 23.0%. Histological follow-up was available for 856 cases (49.5%). The ROM was 13.1%, 4.8%, 26.9%, 84.3%, and 94.5% for Categories 1-5, respectively. CONCLUSIONS IAC-YS showed a higher proportion of cases of Category 1 and a lower proportion of cases of Category 3 than the CJS. Despite these differences, both systems were equivalent in their impact on daily medical care, although ROM differed for the content of Categories 1 and 3. Quality assurance parameters for our data based on IAC-YS are comparable to those of CJS.

    2026DIAGNOSTIC CYTOPATHOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1502 篇论文

    合作机构(100)

    名古屋大学合作论文 315
    京都大学合作论文 167
    东京大学合作论文 138
    名古屋大学医院合作论文 98
    Toyohashi Municipal Hospital合作论文 84
    名古屋市立大学合作论文 78
    长崎大学合作论文 74
    近畿大学合作论文 73
    京都府立医科大学合作论文 70
    九州大学合作论文 68

    机构统计